Previous studies indicated that the expression of miRNA-330 was significantly decreased in human prostate cancer, melanoma skin cancer, and colorectal cancer, which inversely correlated with its direct target specificity protein 1 (Sp1), E2F1 transcription factors, and thymidylate synthase (TYMS) expression. This evidence concerns the gene SP1 and prostate carcinoma.